Abeona Therapeutics Inc. (ABEO)

$4.06

-0.11

(-2.64%)

Market is closed - opens 7 PM, 28 May 2024

Insights on Abeona Therapeutics Inc.

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 67.0% return, outperforming this stock by 37.7%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 238.7% return, outperforming this stock by 328.9%

Performance

  • $4.04
    $4.32
    $4.06
    downward going graph

    0.49%

    Downside

    Day's Volatility :6.48%

    Upside

    6.02%

    downward going graph
  • $2.83
    $9.01
    $4.06
    downward going graph

    30.3%

    Downside

    52 Weeks Volatility :68.59%

    Upside

    54.94%

    downward going graph

Returns

PeriodAbeona Therapeutics Inc.Russel 2000Index (Russel 2000)
3 Months
-46.15%
0.0%
0.0%
6 Months
-15.59%
0.0%
0.0%
1 Year
29.3%
0.0%
0.0%
3 Years
-90.16%
-21.4%
-21.4%

Highlights

Market Capitalization
171.7M
Book Value
$0.56
Earnings Per Share (EPS)
-2.53
PEG Ratio
0.0
Wall Street Target Price
15.75
Profit Margin
0.0%
Operating Margin TTM
-1377.14%
Return On Assets TTM
-46.99%
Return On Equity TTM
-260.6%
Revenue TTM
3.5M
Revenue Per Share TTM
0.16
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
-28.0M
EBITDA
-45.9M
Diluted Eps TTM
-2.53
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.71
EPS Estimate Next Year
-1.46
EPS Estimate Current Quarter
-0.51
EPS Estimate Next Quarter
-0.53

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Abeona Therapeutics Inc.(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 287.93%

Current $4.06
Target $15.75

Technicals Summary

Sell

Neutral

Buy

Abeona Therapeutics Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Abeona Therapeutics Inc.
Abeona Therapeutics Inc.
24.54%
-15.59%
29.3%
-90.16%
-97.38%
Moderna, Inc.
Moderna, Inc.
54.31%
114.37%
31.98%
-5.11%
673.49%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
11.53%
23.42%
35.86%
98.13%
219.88%
Novo Nordisk A/s
Novo Nordisk A/s
7.24%
30.97%
66.95%
238.66%
467.54%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
14.96%
30.49%
38.47%
120.96%
164.5%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Abeona Therapeutics Inc.
Abeona Therapeutics Inc.
0.06
NA
0.0
-1.71
-2.61
-0.47
NA
0.56
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.6
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.99
28.99
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
46.75
46.75
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.23
29.23
0.53
17.14
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Abeona Therapeutics Inc.
Abeona Therapeutics Inc.
Buy
$171.7M
-97.38%
0.06
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$63.9B
673.49%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.0B
219.88%
28.99
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$605.7B
467.54%
46.75
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$116.3B
164.5%
29.23
39.46%

Institutional Holdings

  • Nantahala Capital Management, LLC

    16.45%
  • Adage Capital Partners Gp LLC

    11.88%
  • Millennium Management LLC

    7.26%
  • Vanguard Group Inc

    4.03%
  • Western Standard LLC

    2.95%
  • AIGH Capital Management, LLC

    2.88%

Company Information

abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t

Organization
Abeona Therapeutics Inc.
Employees
84
CEO
Dr. Vishwas Seshadri M.B.A., Ph.D.
Industry
Health Technology

FAQs